We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A selective norepinephrine reuptake inhibitor for the treatment of major depression.
- Authors
Gutierrez; Stimmel, Mary A.
- Abstract
Reboxetine is the first of a new class of drugs known as selective norepinephrine reuptake inhibitors for the treatment of major depression. It is expected to be launched at the end of 1999. Comparative clinical trials show reboxetine to be as effective as imipramine and desipramine in adults and the elderly. Additional studies show it to be as effective as fluoxetine in depressed patients overall and more effective than fluoxetine in the severely depressed. Reboxetine appears to lack the cognitive and cardiovascular adverse effects of TCAs and to be associated with fewer anticholinergic side effects than TCAs and significantly fewer gastrointestinal and sexual adverse effects than SSRIs. The most common adverse effects reported with reboxetine include dry mouth, constipation, increased sweating, tachycardia, and insomnia. Reboxetine has no inhibitory effects on the CYP450 isoenzymes involved in drug metabolism. The effective dosage range is 8 to 10 mg/day (4 to 6 mg/day in the elderly) given in two divided doses. INSET: Formulary considerations..
- Publication
Formulary, 1999, Vol 34, Issue 11, p909
- ISSN
1082-801X
- Publication type
Academic Journal